Active Pass Pharmaceuticals Receives $3.6 Million CDN Grant From NIH For Development Of Novel Treatment For Secretory Diarrhea
10/19/2005 5:08:44 PM
Active Pass Pharmaceuticals today announced receipt of a grant of $3.6 M CDN ($2.8 M USD) for development of a novel treatment for secretory diarrhea. The award was made by the National Institute of Allergy and Infectious Diseases (NIAID) branch of the National Institute of Health (NIH) in the United States. Dr. David MacDonald, President and CEO of Active Pass, is the principal investigator.
comments powered by